Drug intelligence / Profile preview

TQB3006

Development stage: Phase 1
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

TQB3006 is an orally administered small molecule inhibitor being developed by Chia Tai Tianqing Pharmaceutical Group for the treatment of cancer. It is currently in phase 1 clinical trials for advanced malignant tumors, with studies focused on evaluating its safety, tolerability, pharmacokinetics, and preliminary efficacy. The specific molecular target and mechanism of action have not been publicly disclosed as of the latest updates. TQB3006 represents a new molecular entity in oncology drug development.

Beyond the preview

Go deeper on TQB3006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQB3006.

Explore the full profile